Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

@inproceedings{Kleinert2011ImpactOP,
  title={Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study},
  author={Stefan Kleinert and H. -P. Tony and Andreas Krause and Martin Feuchtenberger and Siegfried Wassenberg and Constanze Richter and Ekkehard R{\"o}ther and Wolfgang Spieler and Holger Gnann and Bianca Maria Wittig},
  booktitle={Rheumatology International},
  year={2011}
}
The objective of this study was to use data from a noninterventional study to evaluate the effectiveness of adalimumab in rheumatoid arthritis (RA) patients during routine clinical practice and to explore the potential impact of patient and disease characteristics in response to adalimumab therapy. A total of 2,625 RA patients with specified data at baseline (prior to initiating adalimumab treatment) and 12 months entered this study between April 2003 and March 2009. We evaluated response to… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis : data from a German noninterventional observational study .
The objective of this study was to use data from a noninterventional study to evaluate the effectiveness of adalimumab in rheumatoid arthritis ( RA ) patients during routine clinical practice and to explore the potential impact of patient and disease characteristics in response to adalimumab therapy .
The objective of this study was to use data from a noninterventional study to evaluate the effectiveness of adalimumab in rheumatoid arthritis ( RA ) patients during routine clinical practice and to explore the potential impact of patient and disease characteristics in response to adalimumab therapy .
All Topics